Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of oral BAY 63-2521 (riociguat) in CTEPH
2008-003539-19Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and secondary pulmonary hypertension, sponsored by Bayer. Primary endpoint: Long-term safety and tolerability of riociguat. Started Oct 2008; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)secondary pulmonary hypertension
Beyond the preview
Go deeper on 2008-003539-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003539-19.